.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,843,889

« Back to Dashboard

Details for Patent: 5,843,889

Title: Glycopeptide antibiotic derivatives
Abstract:The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity aginst a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
Inventor(s): Cooper; Robin D. G. (Indianapolis, IN), Huff; Bret E. (Mooresville, IN), Nicas; Thalia I. (Indianapolis, IN), Quatroche; John T. (Indianapolis, IN), Rodriguez; Michael J. (Indianapolis, IN), Snyder; Nancy J. (Charlottesville, IN), Staszak; Michael A. (Indianapolis, IN), Thompson; Richard C. (Frankfort, IN), Wilkie; Stephen C. (Indianapolis, IN), Zweifel; Mark J. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Mar 12, 1997
Application Number:08/816,224
Claims:1. A compound of the formula: ##STR9## or salt thereof, wherein: R.sup.6 is vancosaminyl; and

R.sup.7 is (C.sub.1 -C.sub.12 alkyl)--R.sub.8 and is attached to the amino group of R.sup.6 ;

R.sup.8 is a group of the formula: ##STR10## wherein q is 0 to 4; R.sup.12 is independently selected from the group consisting of:

(i) halo,

(ii) nitro,

(iii) (C.sub.1 -C.sub.6)alkyl,

(iv) (C.sub.1 -C.sub.6)alkoxy,

(v) halo-(C.sub.1 -C.sub.6)alkyl,

(vi) halo-(C.sub.1 -C.sub.6)alkoxy,

(vii) hydroxy, and

(vii) (C.sub.1 -C.sub.6)thioalkyl;

r is 1 to 5; provided that the sum of q and r is no greater than 5;

Z is selected from the group consisting of:

(i) a single bond,

(ii) divalent (C.sub.1 -C.sub.6)alkyl unsubstituted or substituted with hydroxy, (C.sub.1 -C.sub.6)alkyl, or (C.sub.1 -C.sub.6)alkoxy,

(iii) divalent (C.sub.2 -C.sub.6)alkenyl,

(iv) divalent (C.sub.2 -C.sub.6)alkynyl, and

(v) a group of the formula --(C(R.sup.14).sub.2).sub.s --R.sup.15 -- or --R.sup.15 -- (C(R.sup.4).sub.2).sub.s --, wherein s is 0-6; wherein each R.sup.14 substituent is independently selected from hydrogen, (C.sub.1 -C.sub.6)-alkyl, and (C.sub.4 -C.sub.10) cycloalkyl; and R.sup.15 is selected from --O--, --S--, --SO--, --SO.sub.2 --, --SO.sub.2 --O--, --C(O)--, --OC(O)--, --C(O)O--, --NH--, --N(C.sub.1 -C.sub.6 alkyl)-, --C(O)NH--, --NHC(O)--, and N.dbd.N;

R.sup.13 is independently selected from the group consisting of:

(i) (C.sub.4 -C.sub.10) heterocyclyl,

(ii) heteroaryl,

(iii) (C.sub.4 -C.sub.10) cycloalkyl unsubstituted or substituted with (C.sub.1 -C.sub.6) alkyl, and

(iv) phenyl unsubstituted or substituted with 1 to 5 substituents independently selected from: halo, hydroxy, nitro, (C.sub.1 -C.sub.10) alkyl, (C.sub.1 -C.sub.10)alkoxy, halo-(C.sub.1 -C.sub.3)alkoxy, halo-(C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxyphenyl, phenyl, phenyl-(C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.6)alkoxyphenyl, phenyl-(C.sub.2 -C.sub.3)alkynyl, and (C.sub.1 -C.sub.3) alkylphenyl.

2. The compound of claim 1 wherein R.sup.7 represents 4-phenylbenzyl, or a salt thereof.

3. A pharmaceutical composition comprising a compound of claim 11 with one or more pharmaceutically acceptable carriers therefor.

4. A pharmaceutical composition comprising a compound of claim 2 with one or more pharmaceutically acceptable carriers therefor.

5. A method of treating susceptible bacterial infections which comprises administering an antibacterially effective amount of a composition of claim 3 to a host in need of such treatment.

6. A method of treating susceptible bacterial infections which comprises administering an antibacterially effective amount of a composition of claim 4 to a host in need of such treatment.

7. A method of claim 5 wherein the susceptible bacterial infection is caused by a vancomycin-resistant enterococcus.

8. A method of claim 6 wherein the susceptible bacterial infection is caused by a vancomycin-resistant enterococcus.

9. A process for making a compound of claim 1 which comprises

(a) reacting a compound of the formula ##STR11## wherein R.sup.1 is vancosaminyl with an aldehyde corresponding to R.sup.7 as defined in claim 1 in methanol at about 25.degree. C. to about 100.degree. C.;

(b) continuing the reaction until formation of a Schiff's base; and

(c) reducing the Schiff's base by addition of a metal borohydride to the mixture of about 25.degree. C. to about 100.degree. C.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc